Effects of IGF-1 on the Cardiovascular System

Area of Science:

• Cardiovascular Physiology
• Endocrinology
• Molecular Biology

Background:

• Cardiovascular diseases (CVDs) represent a major global health burden with increasing incidence.
• Insulin-like growth factor 1 (IGF-1) is vital for normal cardiovascular system physiology, acting as an anabolic hormone.
• IGF-1 influences metabolic homeostasis, vasorelaxation, cardiac contractility, and cellular survival within the CV system.

Purpose of the Study:

• To review the current literature on the physiological and pathophysiological roles of IGF-1 in the cardiovascular system.
• To highlight the mechanisms by which IGF-1 affects vascular and cardiac functions.
• To discuss the implications of IGF-1 levels for cardiovascular disease risk and potential therapeutic strategies.

Main Methods:

• Literature review of existing studies on IGF-1 and cardiovascular function.
• Analysis of data from animal and human studies.
• Synthesis of findings regarding IGF-1's effects on endothelial nitric oxide synthase (eNOS), inducible NOS (iNOS), and sodium/potassium-adenosine triphosphatase.

Main Results:

• IGF-1 promotes vasorelaxation by regulating eNOS and iNOS activity and influences vascular tone via the sodium/potassium-adenosine triphosphatase.
• Animal studies demonstrate IGF-1's vasorelaxant, anti-apoptotic, and pro-survival effects in the CV system.
• Low serum IGF-1 levels in humans correlate with an elevated risk of cardiovascular and cerebrovascular diseases.

Conclusions:

• IGF-1 is a key hormone in maintaining cardiovascular health through diverse mechanisms.
• Understanding IGF-1's role is critical for developing novel therapies for cardiovascular conditions.
• Further clinical trials are warranted to explore the efficacy and safety of IGF-1-based treatments for CVDs.